- Eli Lilly reported Q2 revenue growth of 48% year-over-year, driven mainly by Zepbound and Mounjaro, and raised full-year revenue guidance to $85-$87 billion.
- Lilly's incretin portfolio kept market leadership and expanded access through the launch of the Medicare GLP-1 bridge program for obesity.
- Oncology, immunology, and neuroscience medicines collectively grew 121%.
- Positive Phase 3 results for retatrutide showed profound weight loss in obesity trials, with a US submission anticipated in Q1 2027.
- Lilly advanced its oral GLP-1 Foundeo with a US submission for type 2 diabetes, secured international approvals for obesity, and made strategic acquisitions to expand its pipeline in emerging therapeutic areas.
Quotes
“profound levels of weight loss”